From the Department of Pathology, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, New Jersey.
Arch Pathol Lab Med. 2023 Jan 1;147(1):46-51. doi: 10.5858/arpa.2022-0070-RA.
CONTEXT.—: Appropriate patient management requires precise and meaningful tumor classification. Breast cancer classification continues to evolve from traditional morphologic evaluation to more sophisticated systems with the integration of new knowledge from research being translated into practice. Breast cancer is heterogeneous at the molecular level, with diversified patterns of gene expression, which is presumably responsible for the difference in tumor behavior and prognosis. Since the beginning of this century, new molecular technology has been gradually applied to breast cancer research on issues pertinent to prognosis (prognostic signature) and therapeutic prediction (predictive signature), and much progress has been made.
OBJECTIVE.—: To summarize the current state and the prospective future of molecular classification of breast cancer.
DATA SOURCES.—: Sources include recent medical literature on molecular classification of breast cancer.
CONCLUSIONS.—: Identification of intrinsic tumor subtypes has set a foundation for refining the breast cancer molecular classification. Studies have explored the genetic features within the intrinsic cancer subtypes and have identified novel molecular targets that led to the innovation of clinical assays to predict a patient's prognosis and to provide specific guidelines for therapeutic decisions. With the development and implication of these molecular tools, we have remarkably advanced our knowledge and enhanced our power to provide optimal management to patients. However, challenges still exist. Besides accurate prediction of prognosis, we are still in urgent need of more molecular predictors for tumor response to therapeutic regimes. Further exploration along this path will be critical for improving a patient's prognosis.
:准确的患者管理需要精确且有意义的肿瘤分类。乳腺癌的分类不断从传统的形态学评估演变为更复杂的系统,同时将研究中的新知识整合到实践中。乳腺癌在分子水平上具有异质性,表现出多样化的基因表达模式,这可能是导致肿瘤行为和预后差异的原因。自本世纪初以来,新的分子技术逐渐应用于乳腺癌研究,涉及与预后(预后标志物)和治疗预测(预测标志物)相关的问题,并取得了很大进展。
:总结乳腺癌分子分类的现状和未来前景。
:数据来源包括乳腺癌分子分类的最新医学文献。
:鉴定内在肿瘤亚型为完善乳腺癌分子分类奠定了基础。研究探索了内在癌症亚型内的遗传特征,并确定了新的分子靶点,从而创新了临床检测方法,以预测患者的预后,并为治疗决策提供具体指导。随着这些分子工具的发展和应用,我们对乳腺癌的认识和为患者提供最佳治疗的能力显著提高。然而,挑战依然存在。除了准确预测预后外,我们仍迫切需要更多的分子预测因子来预测肿瘤对治疗方案的反应。沿着这条道路的进一步探索对于改善患者的预后至关重要。